Milestone Pharmaceuticals, a biopharmaceutical company specializing in cardiovascular medicines, announced it will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026, in New York. The presentation will include a live webcast accessible to conference participants and available for replay on Milestone's website. Milestone's lead product, CARDAMYST™ nasal spray, is FDA-approved for treating acute episodes of paroxysmal supraventricular tachycardia (PSVT) and is being developed for atrial fibrillation-related conditions. This event offers investors insight into the company's progress and future plans.
Barclays increased its price target for Hudbay Minerals to $32 from $30, citing strong growth prospects in copper mining. Despite a recent nearly 30% stock pullback due to market sentiment, Hudbay maintains a solid financial position with near-zero n...
Morgan Stanley reported strong Q2 2026 results, with earnings per share of $3.46 surpassing estimates of $2.89 and revenue of $21.35 billion beating forecasts of $19.67 billion. This marks significant year-over-year growth from $16.79 billion, driven...
The global autoimmune disease therapeutics market is projected to grow from $80.54 billion in 2025 to $137.85 billion by 2035, at a CAGR of 5.52%. Growth is fueled by rising autoimmune disease prevalence, advances in biologics, JAK inhibitors, monocl...
The Vancouver Chinatown Foundation and RBC are hosting Light Up Chinatown! 2026, a free two-day festival on August 8-9 along Columbia Street in Vancouver’s Chinatown. The event features exclusive food collaborations, live music performances, family a...
New research from iSeatz reveals that U.S. travelers are increasingly strategic about travel rewards programs, with 40% treating them as financial optimization tools and 60% belonging to multiple programs. Despite high enrollment, many travelers find...
